Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Proposal for a New Tool to Evaluate Drug Interaction Cases
- J. Horn, P. Hansten, Lingtak-Neander Chan
- Medicine
- The Annals of pharmacotherapy
- 1 April 2007
The assessment of causation for a potential drug interaction requires thoughtful consideration of the properties of both the object and precipitant drugs, patient-specific factors, and the possible… Expand
Toward a complete dataset of drug-drug interaction information from publicly available sources
- Serkan Ayvaz, J. Horn, +9 authors R. Boyce
- Computer Science, Medicine
- J. Biomed. Informatics
- 1 June 2015
TLDR
The proton-pump inhibitors: similarities and differences.
- J. Horn
- Medicine
- Clinical therapeutics
- 1 March 2000
OBJECTIVE
This paper examines the clinical pharmacology of the proton-pump inhibitors (PPIs) and briefly reviews some comparative studies of these agents.
BACKGROUND
PPIs have emerged as the… Expand
Drug interactions analysis and management
- P. Hansten, J. Horn
- Medicine
- 2011
'Drug Interactions Analysis and Management 2014' assists in the prevention and management of drug interactions. Emphasizing management options for improved patient outcomes, the text also and… Expand
- 91
- 6
Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate.
- R. Harrington, J. Woodward, T. Hooton, J. Horn
- Medicine
- Archives of internal medicine
- 11 October 1999
Human immunodeficiency virus 1 (HIV-1) protease inhibitors have dramatically reduced the morbidity and mortality due to HIV-1 infection. However, most of these antiretrovirals are also potent… Expand
Review article: relationship between the metabolism and efficacy of proton pump inhibitors – focus on rabeprazole
- J. Horn
- Medicine
- Alimentary pharmacology & therapeutics
- 1 November 2004
Proton pump inhibitors are now considered the mainstay of treatment for acid‐related disease. Although all proton pump inhibitors are highly effective, the antisecretory effects of different drugs in… Expand
The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers
- A. J. Wright, T. Gomes, M. Mamdani, J. Horn, D. Juurlink
- Medicine
- Canadian Medical Association Journal
- 17 January 2011
Background The macrolide antibiotics clarithromycin and erythromycin may potentiate calcium-channel blockers by inhibiting cytochrome P450 isoenzyme 3A4. However, this potential drug interaction is… Expand
The Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Chronic Idiopathic Constipation (BURDEN-CIC) Study: Results of an Online Questionnaire
- L. Harris, J. Horn, Michele Kissous-Hunt, L. Magnus, E. Quigley
- Medicine
- Advances in Therapy
- 6 November 2017
AbstractIntroduction
There is limited literature comparing the experiences and attitudes of patients with chronic idiopathic constipation (CIC) to those of healthcare professionals (HCPs) treating… Expand
Managing Clinically Important Drug Interactions
- P. Hansten, J. Horn
- Medicine
- 1 July 1998
This handy book provides brief descriptions of clinically important drug interactions selected from the authoritative looseleaf reference, "Drug Interactions Analysis and Management". Only level 1… Expand
Review article: similarities and differences among delayed‐release proton‐pump inhibitor formulations
Proton‐pump inhibitors are acid‐labile, and require an enteric coating to protect them from degradation in the stomach when given orally. However, this leads to delayed absorption and onset of action… Expand